{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:06:36Z","timestamp":1789139196719,"version":"build-2803163510"},"reference-count":56,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jacl.2025.11.012","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T16:13:52Z","timestamp":1763828032000},"page":"476-489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of ongericimab in patients with dyslipidemia: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"20","author":[{"given":"Misbah","family":"Uddin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9558-9338","authenticated-orcid":false,"given":"Asim","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0155-1539","authenticated-orcid":false,"given":"Mohamed Fawzi","family":"Hemida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1009-4372","authenticated-orcid":false,"given":"Muhammad Jibran","family":"Afridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaryab","family":"Bacha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hammad","family":"Iftikhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suleman","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hammad","family":"Saif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aamer","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aizaz Anwar","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjad Ghanim","family":"Al Badri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8632-7854","authenticated-orcid":false,"given":"Muhammad","family":"Waqas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidra","family":"Irfan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8208-0689","authenticated-orcid":false,"given":"Kamil Ahmad","family":"Kamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.jacl.2025.11.012_bib0001","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.11.012_bib0002","unstructured":"American College of Cardiology. [cited 2025 Oct 1]. Guidelines made simple | 2018 Blood Cholesterol Guideline. Accessed Oct 1, 2025 Available from: https:\/\/www.acc.org\/education-and-meetings\/image-and-slide-gallery\/http%3a%2f%2fwww.acc.org%2feducation-and-meetings%2fimage-and-slide-gallery%2fmedia-detail%3fid%3d1764DA8859F1484995627D666CD5F6B7."},{"key":"10.1016\/j.jacl.2025.11.012_bib0003","first-page":"37","article-title":"Chinese guidelines for the management of dyslipidemia in adults","author":"Zhu","year":"2016","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi Chin J Cardiol"},{"issue":"11","key":"10.1016\/j.jacl.2025.11.012_bib0004","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1161\/CIRCULATIONAHA.115.018791","article-title":"Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES)","volume":"133","author":"de Ferranti","year":"2016","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacl.2025.11.012_bib0005","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jacl.2022.09.006","article-title":"A mechanism-based operational definition and classification of hypercholesterolemia","volume":"16","author":"Civeira","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.11.012_tboref0001","unstructured":"Ibrahim M.A., Asuka E., Jialal I. Hypercholesterolemia. StatPearls. StatPearls Publishing; 2025. Accessed July 29, 2025."},{"issue":"20","key":"10.1016\/j.jacl.2025.11.012_bib0007","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide prevalence of familial hypercholesterolemia","volume":"75","author":"Beheshti","year":"2020","journal-title":"JACC"},{"issue":"3","key":"10.1016\/j.jacl.2025.11.012_bib0008","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/nu9030279","article-title":"Trends in determinants of hypercholesterolemia among Chinese adults between 2002 and 2012: results from the National Nutrition Survey","volume":"9","author":"Song","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.jacl.2025.11.012_bib0009","unstructured":"Products - Data Briefs - Number 515 - November 2024. 2024 [cited 2025 July 29]. Accessed July 29, 2025 Available from: https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db515.htm."},{"issue":"34","key":"10.1016\/j.jacl.2025.11.012_bib0010","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Byty\u00e7i","year":"2022","journal-title":"Eur Heart J."},{"issue":"1","key":"10.1016\/j.jacl.2025.11.012_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10408363.2011.646942","article-title":"Molecular pathology of familial hypercholesterolemia, related dyslipidemias and therapies beyond the statins","volume":"49","author":"Faiz","year":"2012","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"11","key":"10.1016\/j.jacl.2025.11.012_bib0012","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70061","article-title":"Clinical pharmacokinetics and pharmacodynamics of ongericimab: a potential long-acting PCSK9 monoclonal antibody in healthy subjects and patients with hypercholesterolemia: randomized, double-blind, placebo-controlled phase Ia and Ib\/II studies","volume":"17","author":"Jiang","year":"2024","journal-title":"Clin Transl Sci"},{"issue":"9","key":"10.1016\/j.jacl.2025.11.012_bib0013","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/j.numecd.2024.04.011","article-title":"Efficacy and safety of ongericimab given by prefilled syringe or autoinjector in primary hypercholesterolemia and mixed hyperlipidemia","volume":"34","author":"Zhao","year":"2024","journal-title":"Nut Metab Cardiovascular Diseases."},{"key":"10.1016\/j.jacl.2025.11.012_bib0014","doi-asserted-by":"crossref","first-page":"120408","DOI":"10.1016\/j.atherosclerosis.2025.120408","article-title":"Efficacy and safety of ongericimab in Chinese statin-intolerant patients with primary hypercholesterolemia or mixed dyslipidemia: a randomized, placebo-controlled phase 3 trial","volume":"407","author":"Shao","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2025.11.012_bib0015","doi-asserted-by":"crossref","first-page":"119120","DOI":"10.1016\/j.atherosclerosis.2025.119120","article-title":"Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: A randomized, double-blind, placebo-controlled phase 3 trial","volume":"403","author":"Lin","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2025.11.012_bib0016","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. [cited 2025 Apr 27]. Accessed Apr 27, 2025 Available from: https:\/\/training.cochrane.org\/handbook\/current."},{"key":"10.1016\/j.jacl.2025.11.012_bib0017","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.jacl.2025.11.012_bib0018","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.jacl.2025.11.012_bib0019","unstructured":"RoB 2: a revised tool for assessing risk of bias in randomised trials BMJ. [cited 2025 Apr 28]. Accessed April 28, 2025 Available from: https:\/\/www.bmj.com\/content\/366\/bmj.l4898.long."},{"issue":"4","key":"10.1016\/j.jacl.2025.11.012_bib0020","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"7300","key":"10.1016\/j.jacl.2025.11.012_bib0021","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1136\/bmj.322.7300.1479","article-title":"Forest plots: trying to see the wood and the trees","volume":"322","author":"Lewis","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2025.11.012_bib0022","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","DOI":"10.1136\/bmj.327.7414.557"},{"key":"10.1016\/j.jacl.2025.11.012_bib0023","unstructured":"GRADE handbook [Internet]. [cited 2025 Apr 30]. Accessed April 30, 2025 Available from: https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html."},{"issue":"7651","key":"10.1016\/j.jacl.2025.11.012_bib0024","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \u201cquality of evidence\u201d and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.jacl.2025.11.012_bib0025","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"issue":"32","key":"10.1016\/j.jacl.2025.11.012_bib0026","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.jacl.2025.11.012_bib0027","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jacl.2025.11.012_bib0028","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.11.012_bib0029","first-page":"33","article-title":"Efficacy and safety of proprotein convertase subtilisin\/kexin type 9 inhibitors as adjuvant treatments for patients with hypercholesterolemia treated with statin","author":"Huang","year":"2022","journal-title":"Syst Rev Netw Meta-Anal Front Pharmacol."},{"issue":"16","key":"10.1016\/j.jacl.2025.11.012_bib0030","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.jacl.2025.11.012_bib0031","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jacl.2025.11.012_bib0032","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","article-title":"A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk","volume":"4","author":"Sniderman","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"4","key":"10.1016\/j.jacl.2025.11.012_bib0033","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.jacl.2025.11.012_bib0034","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jacc.2021.01.027","article-title":"Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients","volume":"77","author":"Johannesen","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.jacl.2025.11.012_bib0035","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","article-title":"Apolipoprotein B particles and cardiovascular disease","volume":"4","author":"Sniderman","year":"2019","journal-title":"Narrat Rev JAMA Cardiol"},{"issue":"6","key":"10.1016\/j.jacl.2025.11.012_bib0036","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"39","key":"10.1016\/j.jacl.2025.11.012_bib0037","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.jacl.2025.11.012_bib0038","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"PCSK9 inhibition, and cardiovascular risk: insights from the FOURIER trial","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jacl.2025.11.012_bib0039","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/FJC.0000000000000963","article-title":"Lipoprotein(a) reduction with proprotein convertase subtilisin\/kexin type 9 inhibitors: a systematic review and meta-analysis","volume":"77","author":"Farmakis","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"10.1016\/j.jacl.2025.11.012_bib0040","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jacl.2025.11.012_bib0041","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jacl.2025.11.012_bib0042","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"Boffa","year":"2016","journal-title":"J Lipid Res"},{"issue":"13","key":"10.1016\/j.jacl.2025.11.012_bib0043","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2014.01.006","article-title":"Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1300 patients in 4 phase II trials","volume":"63","author":"Raal","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.jacl.2025.11.012_bib0044","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1016\/j.jacc.2021.06.017","article-title":"JACC focus semin 19","volume":"78","author":"Ogunniyi","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.jacl.2025.11.012_bib0045","first-page":"939","article-title":"Lipoprotein(a) reduction with small interfering RNA olpasiran in patients with ASCVD: a randomized clinical trial","volume":"328","author":"O\u2019Donoghue","year":"2022","journal-title":"JAMA"},{"issue":"10057","key":"10.1016\/j.jacl.2025.11.012_bib0046","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomized, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.jacl.2025.11.012_bib0047","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jacl.2025.11.012_bib0048","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"issue":"9943","key":"10.1016\/j.jacl.2025.11.012_bib0049","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S0140-6736(14)61217-4","article-title":"HDL and cardiovascular disease","volume":"384","author":"Rader","year":"2014","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.jacl.2025.11.012_bib0050","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment","volume":"36","author":"Stroes","year":"2015","journal-title":"Aetiol Manag Eur Heart J."},{"issue":"12","key":"10.1016\/j.jacl.2025.11.012_bib0051","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006910","article-title":"Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta-analysis of 35 randomized controlled trials","volume":"6","author":"Karatasakis","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"10.1016\/j.jacl.2025.11.012_bib0052","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"Cognitive function in a randomized trial of evolocumab","volume":"377","author":"Giugliano","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jacl.2025.11.012_bib0053","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/eurheartj\/ehz430","article-title":"Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials","volume":"43","author":"Guedeney","year":"2022","journal-title":"Eur Heart J"},{"issue":"39","key":"10.1016\/j.jacl.2025.11.012_bib0054","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1093\/eurheartj\/ehw292","article-title":"No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies","volume":"37","author":"Colhoun","year":"2016","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.jacl.2025.11.012_bib0055","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jacc.2016.11.037","article-title":"Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials","volume":"69","author":"Robinson","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jacl.2025.11.012_bib56","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.033669","article-title":"Efficacy and Safety of Ongericimab in Chinese Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia","volume":"13","author":"Wang","year":"2024","journal-title":"J Am Heart Assoc"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425005197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425005197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T11:30:02Z","timestamp":1775215802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425005197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1933287425005197"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.11.012","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of ongericimab in patients with dyslipidemia: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}